- Report
- January 2021
- 120 Pages
Global
From €2410EUR$2,500USD£2,061GBP
- Report
- April 2021
- 127 Pages
Global
From €10600EUR$10,995USD£9,066GBP
- Report
- April 2018
Global
From €964EUR$1,000USD£825GBP
- Clinical Trials
- January 2020
- 500 Pages
Global
From €2314EUR$2,400USD£1,979GBP
- Report
- March 2019
- 110 Pages
Global
From €3133EUR$3,250USD£2,680GBP
- Report
- June 2018
- 15 Pages
Global
From €9641EUR$10,000USD£8,245GBP
- Report
- June 2018
- 15 Pages
Global
From €9641EUR$10,000USD£8,245GBP
- Report
- February 2024
- 86 Pages
Global
From €3500EUR$3,889USD£3,098GBP
- Report
- November 2021
- 844 Pages
Global
From €4821EUR$5,000USD£4,123GBP
- Report
- March 2023
- 300 Pages
Global
From €5524EUR$5,730USD£4,725GBP
- Report
- September 2019
Global
From €5177EUR$5,370USD£4,428GBP
Levodopa is a drug used to treat Parkinson's disease, a neurological disorder that affects movement. It is a dopamine precursor, meaning it is converted into dopamine in the brain, which helps to reduce the symptoms of Parkinson's. Levodopa is usually taken in combination with other drugs, such as carbidopa, to increase its effectiveness. It is one of the most commonly prescribed drugs for Parkinson's, and is often the first line of treatment.
Levodopa is a part of the larger Central Nervous System (CNS) drug market, which includes drugs used to treat a variety of neurological disorders. The CNS drug market is highly competitive, with many different companies offering various treatments.
Some of the companies in the Levodopa market include Merck, Novartis, Teva Pharmaceuticals, and Sun Pharmaceuticals. Show Less Read more
